Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced voting results from its annual and special meeting of shareholders held Sept. 22, 2026, with 46,452,598 common shares represented, or 63.58% of outstanding shares as of the record date. Shareholders appointed Zeifmans LLP as auditor, approved setting the board at eight directors and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So as directors. Shareholders also approved changing the company’s legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1.
The legal name change follows adoption of the Helus Pharma business name on Jan. 5 and reflects the company’s anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. This shift is significant because it indicates that Helus Pharma is preparing for the commercialization of its proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom and Ireland.
The board election and name change underscore shareholder confidence in Helus Pharma’s strategic direction. As the company transitions to a commercial-ready entity, it may accelerate its efforts to bring innovative mental health treatments to market. For more information, visit www.helus.com.
The announcement was disseminated through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution. The full press release is available at https://nnw.fm/H4DVg. For complete terms of use and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.
